The Direct Costs of Dravet's Syndrome before and after
Diagnosis Assessment

J 2021

The Direct Costs of Dravet's Syndrome before and after Diagnosis Assessment

ČESKÁ, Katarína, Lukas CESKY, Hana OŠLEJŠKOVÁ a Štefánia AULICKÁ

Základní údaje

Originální název

The Direct Costs of Dravet's Syndrome before and after Diagnosis Assessment

Autoři

ČESKÁ, Katarína (703 Slovensko, domácí), Lukas CESKY (703 Slovensko), Hana OŠLEJŠKOVÁ (203 Česká republika, domácí) a Štefánia AULICKÁ (703 Slovensko, garant, domácí)

Vydání

Neuropediatrics, STUTTGART, GEORG THIEME VERLAG KG, 2021, 0174-304X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30103 Neurosciences

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.696

Kód RIV

RIV/00216224:14110/21:00120783

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1055/s-0040-1718518

UT WoS

000578772900001

Klíčová slova anglicky

epilepsy; Dravet's syndrome; economic study; costs

Štítky

14110320, 14110321, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 17. 5. 2022 08:34, Mgr. Tereza Miškechová

Anotace

V originále

The objective of this study was to estimate the direct cost before and after diagnosis assessment in patients with Dravet's syndrome (DS). The basis of the economic study was to calculate the costs of health care before and after diagnosis of DS. We retrospectively evaluated all SCN1A positive patients with phenotype of DS treated in our hospital. Statistical analyses were performed by IBM SPSS Statistics 24.0 software. After the diagnosis of DS, there was a significant decline of health care costs (-85.6%) an average of Euro29.4 +/- 26.1 monthly per patient. We estimated the monthly costs at Euro204.5 +/- 167 (median: Euro193.9, range: Euro35.5-534.4) per patient before DS diagnosis. The major cost was for hospitalization in neurological department: Euro43.3 +/- 52 (median: Euro21.9, range: Euro9.5-179.4) per patient. Minimal cost per patient per months before DS diagnosis was cost of psychological testing/care and complementary rehabilitation (0.13 and 0.6% of total cost). After DS diagnosis, the major cost was focused on nonhospitalization care of patients (64.8%), minimal (Euro0) for genetic testing and major for outpatient care (18%, mean: Euro5.3, median: Euro7). DS results in essential health care utilization and high financial burden before diagnosis elucidation caused by repeated hospitalization and extensive diagnostics tests of "epileptic encephalopathy of unknown etiology." The results of this study point out that early assessment of the diagnosis leads to significant decrease of the financial costs because of adequate therapeutic management and exclusion of redundant diagnostic testing after elucidation of correct diagnosis.

Citovat

ČESKÁ, Katarína, Lukas CESKY, Hana OŠLEJŠKOVÁ a Štefánia AULICKÁ. The Direct Costs of Dravet's Syndrome before and after Diagnosis Assessment. Neuropediatrics. STUTTGART: GEORG THIEME VERLAG KG, 2021, roč. 52, č. 01, s. 6-11. ISSN 0174-304X. Dostupné z: https://dx.doi.org/10.1055/s-0040-1718518.

@article{1688921,
   author = {Česká, Katarína and Cesky, Lukas and Ošlejšková, Hana and Aulická, Štefánia},
   article_location = {STUTTGART},
   article_number = {01},
   doi = {http://dx.doi.org/10.1055/s-0040-1718518},
   keywords = {epilepsy; Dravet's syndrome; economic study; costs},
   language = {eng},
   issn = {0174-304X},
   journal = {Neuropediatrics},
   title = {The Direct Costs of Dravet's Syndrome before and after Diagnosis Assessment},
   url = {https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0040-1718518},
   volume = {52},
   year = {2021}
}

TY  - JOUR
ID  - 1688921
AU  - Česká, Katarína - Cesky, Lukas - Ošlejšková, Hana - Aulická, Štefánia
PY  - 2021
TI  - The Direct Costs of Dravet's Syndrome before and after Diagnosis Assessment
JF  - Neuropediatrics
VL  - 52
IS  - 01
SP  - 6-11
EP  - 6-11
PB  - GEORG THIEME VERLAG KG
SN  - 0174304X
KW  - epilepsy
KW  - Dravet's syndrome
KW  - economic study
KW  - costs
UR  - https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0040-1718518
L2  - https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0040-1718518
N2  - The objective of this study was to estimate the direct cost before and after diagnosis assessment in patients with Dravet's syndrome (DS). The basis of the economic study was to calculate the costs of health care before and after diagnosis of DS. We retrospectively evaluated all SCN1A positive patients with phenotype of DS treated in our hospital. Statistical analyses were performed by IBM SPSS Statistics 24.0 software. After the diagnosis of DS, there was a significant decline of health care costs (-85.6%) an average of Euro29.4 +/- 26.1 monthly per patient. We estimated the monthly costs at Euro204.5 +/- 167 (median: Euro193.9, range: Euro35.5-534.4) per patient before DS diagnosis. The major cost was for hospitalization in neurological department: Euro43.3 +/- 52 (median: Euro21.9, range: Euro9.5-179.4) per patient. Minimal cost per patient per months before DS diagnosis was cost of psychological testing/care and complementary rehabilitation (0.13 and 0.6% of total cost). After DS diagnosis, the major cost was focused on nonhospitalization care of patients (64.8%), minimal (Euro0) for genetic testing and major for outpatient care (18%, mean: Euro5.3, median: Euro7). DS results in essential health care utilization and high financial burden before diagnosis elucidation caused by repeated hospitalization and extensive diagnostics tests of "epileptic encephalopathy of unknown etiology." The results of this study point out that early assessment of the diagnosis leads to significant decrease of the financial costs because of adequate therapeutic management and exclusion of redundant diagnostic testing after elucidation of correct diagnosis.
ER  -

ČESKÁ, Katarína, Lukas CESKY, Hana OŠLEJŠKOVÁ a Štefánia AULICKÁ. The Direct Costs of Dravet's Syndrome before and after Diagnosis Assessment. \textit{Neuropediatrics}. STUTTGART: GEORG THIEME VERLAG KG, 2021, roč.~52, č.~01, s.~6-11. ISSN~0174-304X. Dostupné z: https://dx.doi.org/10.1055/s-0040-1718518.

Podrobný výpis o publikaci